EntreMed's ENMD-2076 Demonstrates Antitumor Activity In Multiple Myeloma Model
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-981693, the free base of ENMD-2076.
Hip And Knee Replacement Patients Not Receiving Treatment To Reduce Blood Clot Risk
Hip and knee replacement surgery patients - who are often elderly - are at increased risk of developing potentially life-threatening thrombosis, or blood clots. Nevertheless, according to a study by Dr. Elham Rahme of the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University, most patients in Quebec do not receive the recommended treatment to prevent a thrombosis.
Rivaroxaban Phase III Pivotal Data Presented At EFORT Annual Meeting
Results from a pivotal Phase III clinical trial demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery.
New Meta-Analysis Confirms Safety Profile For NeoRecormon In Treating Anaemia In Cancer Patients
Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2, 301 cancer patients shows that treating anaemia with NeoRecormon(R) (epoetin beta) has no negative impact on survival, tumour progression or deaths caused by blood clots, when used within its approved indications (1).
Potential Impact Of Limiting Erythropoiesis-Stimulating Agent Availability On Frequency Of Blood Transfusions
Data from three observational studies reported at the American Society of Clinical Oncology (ASCO) Annual Meeting evaluated transfusion-related outcomes in cancer chemotherapy patients with various hemoglobin (Hb) levels prior to or during administration of erythropoiesis-stimulating agents (ESAs).
Johns Hopkins Researchers Develop Human Stem Cell Line Containing Sickle Cell Anemia Mutation
Researchers at Johns Hopkins have established a human cell-based system for studying sickle cell anemia by reprogramming somatic cells to an embryonic stem cell like state. Publishing online in Stem Cells on May 29, the team describes a faster and more efficient method of reprogramming cells that might speed the development of stem cell therapies.
Boehringer Ingelheim Announces First Positive Health Technology Assessments For Novel Oral Anticoagulant Pradaxa R dabigatran Etexilate
The Scottish Medicines Consortium (SMC) has accepted Pradaxa (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the prevention of venous thromboembolic events in adults who have undergone total hip or knee replacement surgery.
Black And White Diabetes Patients Being Treated Differently By Same Physicians
According to a study published in the Archives of InternalMedicine, physicians are treating blackdiabetes patients differently than white diabetes patients. Thomas D.Sequist, M.D., M.P.H.
ZymoGenetics Announces FDA Approval Of RECOTHROMTM 20,000-IU Vial Size And Co-Packaging With Spray Kit
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that the United States Food and Drug Administration (FDA) has approved a Prior Approval Supplement application for a 20, 000 international unit (IU) vial of RECOTHROMTM Thrombin, topical (Recombinant) and also approved co-packaging of the 20, 000-IU vial with the ZymoGenetics Spray Applicator Kit.
Sanofi-aventis Withdraws Its Marketing Authorisation Application ForAquilda satavaptan , Europe
The European Medicines Agency (EMEA) has been formally notified by Sanofi-Aventis of its decision to withdraw the application for a centralised marketing authorisation for the medicine Aquilda (satavaptan) 5 and 25 mg film-coated tablets. Aquilda was intended to be used for the treatment of euvolaemic and hypervolaemic dilutional hyponatraemia, a metabolic condition in which the body's blood sodium level falls below normal.